Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

This Phase 1 trial is testing a new personalized cell therapy (TCR-T cell therapy) that targets cancer cells carrying a specific mutation called KRAS G12D, which is common in several solid tumors. Researchers engineer the patient's own immune cells to recognize and attack cancer cells with this mutation. **You may be eligible if...** - You are 18 or older with advanced or metastatic solid tumor cancer (including lung, colorectal, pancreatic, endometrial, or other solid tumors) - Your tumor has a confirmed KRAS G12D mutation - You carry specific immune cell types (HLA-C*08:02 or HLA-A*11:01/A*11:02) - You have received at least one prior standard treatment - You have measurable disease and a good performance status (ECOG 0–1) **You may NOT be eligible if...** - You do not have the required KRAS G12D mutation or the specific immune cell types - You have had prior gene therapy, CAR-T therapy, or organ/stem cell transplant - You have active brain metastases or a history of stroke within the past year - You have significant heart disease or heart failure - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.